By Spondylitis Association of America
Wednesday, February 27, 2019
The following is an announcement from SAA about a third party clinical trial. SAA is not affiliated with this study, the researchers, or the drug manufacturer.
A phase 2/3 clinical trial is now recruiting patients over the age of 18 with active psoriatic arthritis (PsA), ankylosing spondylitis (AS), or non-radiographic axial spondyloarthritis (nr-axSpA) to participate in a multiple-dose, long-term extension study (4-years). This study is a follow up, and is recruiting those who have previously participated in the parent study involving the medication Tilldrakizumab.
The purpose of the trial titled, “A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis” is to study the safety and efficacy of Tildrakizumab in those with psoriatic arthritis (PsA), ankylosing spondylitis (AS) or non-radiographic axial spondyloarthritis (nr-axSpA).
Study qualifications include:
More information can be found on the Clinical Trials website.
Please visit the clinical trials study locations page for contact information, and to locate specific study locations. You can also contact the study sponsor, Sun Pharma Global FZE, for more information at email@example.com
Learn more about participating in Clinical Studies
Visit our careers page for available positions
16360 Roscoe Blvd. Ste. 100Van Nuys, CA 91406
(800) 777-8189 U.S. only
or (818) 892-1616*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.